Immunotherapy and chemotherapy--a practical partnership.
This article discusses how recent data have altered the way we understand how dying tumour cells, particularly those killed by chemotherapy, engage with antitumour immune responses. These data have significant implications for the development of new protocols combining chemotherapy with immunotherapy, indicating an exciting potential for therapeutic synergy with general applicability to many cancer types.
Lake
Richard A
RA
Tumour Immunology Group, School of Medicine and Pharmacology, Western Australian Institute for Medical Research, Perth, 6009, Australia. rlake@cyllene.uwa.edu.au
Robinson
Bruce W S
BW
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D009369:Neoplasms / Q000628:therapy*
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents